Acute Myeloid Testing Market at a CAGR of 13.70% in the forecast period of 2022-2029. Introduction
The acute myeloid leukemia (AML) testing market has become a critical segment within the broader field of oncology diagnostics. AML is an aggressive cancer of the blood and bone marrow characterized by the rapid growth of abnormal myeloid cells. It accounts for a significant proportion of leukemia cases worldwide and is associated with high morbidity and mortality rates....
0 aandelen
4 Views
0 voorbeeld